Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Submission to be reviewed under FDA real-time oncology review and Project Orbis
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
The companies will work with investigators to share the results with the scientific community
Subscribe To Our Newsletter & Stay Updated
